All News

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Researchers found that patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) may benefit from bridging radiation therapy (RT) ahead of receiving chimeric antigen receptor (CAR) T-cell therapy.

Kathy Oubre, MS, CEO of Pontchartrain Cancer Center, speaks on the unique perspectives and challenges smaller health care practices may face when entering into alternative payment models and shares key insights for addressing these issues.

The FDA has granted fast track designation to IDE161 for use in adult patients with advanced or metastatic hormone receptor–positive, HER2-negative breast cancer harboring BRCA1/2 mutations who have progressed after at least 1 hormonal therapy, a CDK4/6 inhibitor, and a poly (ADP-ribose) polymerase inhibitor.

These findings support the importance of children with atopic dermatitis (AD) receiving patch testing to consider allergic contact dermatitis as a comorbidity.

A poster presented at the 40th National Oncology Conference addressed several hot topics in the oncology treatment and research space: addressing medical mistrust in underresourced communities, partnering with trusted organizations to improve health equity, and increasing inclusivity in research.

In a multidisciplinary follow-up study, researchers analyzed bone health decline and the effects of nusinersen in patients with spinal muscular atrophy (SMA) types 2 and 3.

Fresenius Vascular Care's own research reportedly showed these surgeries not only failed to benefit patients with end-stage renal disease, but also potentially damaged their ability to receive essential dialysis treatment.

The FDA has approved Tofidence, the first tocilizumab biosimilar in the United States, which will be used to treat rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.

Sara Horst, MD, MPH, FACG, gave physicians tips on maintaining the personable aspects of in-person appointments during telehealth appointments and shared how digital health has helped her treat patients.

Americans with college degrees live longer than those without; pre-exposure prophylaxis (PrEP) accessibility is low for Black women; new COVID-19 vaccine access is proving difficult for some Americans, as the COVID-19 vaccine card is being phased out.

More ovarian cancer drug approvals and treatments have become available since 2014 than in the preceding 60 years combined, emphasized Rebecca Brooks, MD, UC Davis Health.

Prevalence of hepatitis B virus (HBV) decreased in people living with HIV in Germany when vaccination coverage increased due to general recommendations and catch-up vaccination efforts.

Kaiser Permanente workers strike; CDC proposes a new policy to decrease sexually transmitted infection (STI) cases; New Jersey court tosses $223.8 million decision against J&J in talc cancer case.

Madeleine McDowell, MD, hopes these data insights will help change providers' behavior in terms of adopting earlier and more regular screening for chronic kidney disease (CKD).

The researchers noted that their findings suggest clinicians and policy makers should encourage hepatitis C virus (HCV) treatment in those with unhealthy alcohol consumption or alcohol use disorder (AUD) rather than create barriers to it.

Among Latino men who have sex with men (MSM), access to and use of pre-exposure prophylaxis (PrEP) remain at suboptimal levels, despite this population of individuals having disproportionately high rates of diagnosed HIV in the United States.

Following discussions with FDA, Takeda will voluntarily withdraw mobocertinib in the United States for adult patients with EGFR exon 20 insertion mutation–positive, locally advanced or metastatic non–small cell lung cancer (NSCLC) based on the outcomes of the phase 3 EXCLAIM-2 trial.

Rhonda Henschel, US Oncology Network's vice president of payer relations, summarized what she learned from the Minnesota Oncology IVBM and discussed new developments in the value-based cancer care space.

Olalekan Ajayi, PharmD, MBA, 2023-2024 president of the Association of Community Cancer Centers (ACCC) and chief operating officer of Highlands Oncology Group, PA, reflects upon his role at ACCC and highlights key topics in oncology care and cancer research that will be presented at the National Oncology Conference.

The CHEST Annual Meeting 2023 will take place in Honolulu, Hawai‘i, from October 8-11, as pulmonologists and researchers from a multitude of specialties convene to discuss pressing topics, including the role of air pollution in lung health.

Fee-for-service care is not really in line with how primary care physicians think or how primary care should be delivered; the crux of value-based care is wanting patients to have the care they want and need, noted Kristin Oaks, DO, Agilon regional medical director at Central Ohio Primary Care.

Younger patients who had colorectal cancer (CRC) stoma had more symptom distress, were depressed and anxious, and had higher supportive care needs.

Major companies committed to joining Medicare drug price negotiations; Boehringer Ingelheim introduced a low-cost version of its adalimumab biosimilar; schools begin to stock naloxone amid rising opioid deaths among young people.

The chosen studies featured various methods to assess medication use initiation, implementation, and/or persistence in patients with chronic obstructive pulmonary disease (COPD).

Severe cases of COVID-19 and COVID-19–related deaths were associated with sickle cell disease.

This year’s 40th National Oncology Conference from the Association of Community Cancer Centers (ACCC) will take place in Austin, Texas, from October 4-6, with content designed to reflect the theme of “Reimagining Innovation.”

In this interview from our recent Institute for Value-Based Medicine® event, Kristine Slam, MD, FACP, Central Ohio Surgical Associates, discusses the positive impact that Choosing Wisely and enhanced recovery after surgery, or EROS, protocols have had on patients receiving treatment for breast cancer.

The October issue of Health Affairs examines the multifaceted aspects of structural racism in health care, exploring historical roots, policy implications, public biases, innovative solutions, and institutional challenges, urging action to confront and dismantle disparities.

Nedosiran (Rivfloza) was approved for children and adults with primary hyperoxaluria type 1 (PH1), according to drugmaker Novo Nordisk.